When it announced the buyout last month, Varian said that it hoped to increase its expertise in cancer care center operations. The deal was financed via a credit facility and cash, Palo Alto-based Varian said, and and prompted the company to cut its fiscal 2019 earnings guidance to adjusted earnings per share of $4.55 to $4.70, down from $4.60 to $4.75 previously.
CTSI reported annual revenues of $43.5 million during the fiscal year ended March 31.
Last month Varian acquired privately-held CyberHeart and its cardiac radioablation tech and inked a cooperative deal with China’s Shangdong Cancer Hospital for proton therapy applications and research. Earlier this month the company paid $185 million for two companies – Endocare and Alicon – to add to its cancer care solutions portfolio.